"By the same token can we also deduce that on a positive note that the BOM, IDMB would have also halted the BOM Phase III trial if they saw no appreciable difference in narrow MACE events and in efficacy with the apabetalone arm as compared with the placebo arm, which they have not. :o)"

I much prefer the Dr. Strange Eye of Agamotto approach that acknowledges all possible outcomes and not just the ones consistent with a biased view of BETonMACE success and/or apabetalone efficacy.

BearDownAZ